- Apr 5
Scientists find core regulatory circuit controlling identity of aggressive lymphoma
Scientists at St. Jude Children’s Research Hospital and Dana-Farber Cancer Institute found a small set of proteins that maintain...
- Jun 16, 2022
Bortezomib extends survival of children with newly diagnosed T-cell lymphoblastic lymphoma
The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell ...
- Jun 13, 2022
Researchers Identify RAD21 Variants in Pediatric Lymphoblastic Leukemia or Lymphoma
A recent study involving children with hematologic malignancies has suggested that mutations in a portion of a cohesin gene known as...
- Mar 28, 2022
Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
Adding the proteasome inhibitor bortezomib to chemotherapy significantly improved overall survival in children and young adults with...
- Dec 7, 2021
Yale-led studies open doors for treatment of lymphoma and neuroblastoma cancers
Two new Yale-led studies elucidate protein structure and function of ALK, a protein receptor, which could contribute to new treatments...
- Jul 2, 2021
FDA Approves Rylaze as Alternative for Patients with ALL and Lymphoblastic Lymphoma
New FDA approval means that pediatric and adult patients with acute lymphoblastic leukemia (ALL) and lympoblastic lymphoma who are...
- Dec 7, 2020
Long-Term Survivors of Childhood Hodgkin Lymphoma at Increased Risk for Neurocognitive Impairment
"Despite receiving no neurotoxic therapy directed to the central nervous system, long-term survivors of childhood Hodgkin lymphoma (HL)...
- Jul 6, 2020
Rituximab Regimen Improves Survival in Children With Aggressive B-Cell Lymphoma
Adding rituximab (Rituxan, Truxima) to chemotherapy may be a new standard for treating children and young adults newly diagnosed with...